AbbVie Inc (ABBV)

Add to Watchlists
Create an Alert
Quickflows
104.89 +0.69  +0.66% NYSE Nov 27, 20:00 USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All ABBV News

News

View All Events

Events

Date Type Description
02/05/2021 Earnings AbbVie Inc Fourth Quarter Earnings for 2020 Release
02/05/2021 08:00 CST Misc AbbVie Inc Fourth Quarter Earnings Conference Call for 2020
01/14/2021 Dividends Amount: 1.30, Declared Date: Oct 30 2020, Pay Date: Feb 16 2021
10/30/2020 Earnings AbbVie Inc Third Quarter Earnings Result for 2020
10/30/2020 08:00 CDT Misc AbbVie Inc Third Quarter Earnings Conference Call for 2020
10/14/2020 Dividends Amount: 1.18, Declared Date: Sep 11 2020, Pay Date: Nov 16 2020
07/31/2020 08:00 CDT Misc AbbVie Inc Second Quarter Earnings Conference Call for 2020
07/31/2020 Earnings AbbVie Inc Second Quarter Earnings Result for 2020
07/14/2020 Dividends Amount: 1.18, Declared Date: Jun 17 2020, Pay Date: Aug 14 2020
05/08/2020 09:00 CDT Misc AbbVie Inc Annual General Meeting for 2019
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 40.65B
Total Expenses (TTM) 29.08B
Net Income (TTM) 7.381B

Balance Sheet View Statement

Total Assets (Quarterly) 149.62B
Total Liabilities (Quarterly) 134.33B
Shareholders Equity (Quarterly) 15.27B

Cash Flow Statement View Statement

Cash from Operations (TTM) 16.01B
Cash from Investing (TTM) -37.54B
Cash from Financing (TTM) 18.80B

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.abbvieinvestor.com
  • Investor Relations URL: http://www.abbvieinvestor.com/phoenix.zhtml?c=251551&p=irol-IRHome
  • HQ State/Province: Illinois
  • Sector: Healthcare
  • Industry: Drug Manufacturers - General
  • Equity Style: Large Cap/Value
  • Next Earnings Release: Feb. 05, 2021
  • Last Earnings Release: Oct. 30, 2020
  • Next Ex-Dividend Date: Jan. 14, 2021
  • Last Ex-Dividend Date: Oct. 14, 2020
  • Description: AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 104.89
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
FIJYX Fidelity Advisor® Biotechnology Z 17.87%
FBIOX Fidelity® Select Biotechnology 7.67%
XLV Health Care Select Sector SPDR® ETF 4.51%
VHT Vanguard Health Care ETF 3.13%
SDY SPDR® S&P Dividend ETF 2.05%
CIRFX American Funds Capital Income Bldr 529F 1.67%
VHYAX Vanguard High Dividend Yield Index Adm 1.56%
VYM Vanguard High Dividend Yield ETF 1.56%
CMLFX American Funds American Mutual 529F 1.41%
VIVAX Vanguard Value Index Inv 1.22%
VTV Vanguard Value ETF 1.22%
IWF iShares Russell 1000 Growth ETF 0.99%

Comparables

Edit
AMGN Amgen Inc
JNJ Johnson & Johnson
LLY Eli Lilly and Co
MRK Merck & Co Inc
PFE Pfizer Inc

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.